Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 178

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis

Gu, Xiao-Bin, Tian, Tian, Tian, Xiao-Jing, Zhang, Xiao-Jun·2015·Scientific Reports
DOI 10.1038/srep12493
Open this paper in CoChat — free account

Abstract

Published data on the prognostic significance of neutrophil-to-lymphocyte ratio (NLR) in non-small cell lung cancer (NSCLC) are controversial. We performed a meta-analysis to more accurately assess its prognostic value. The analysis was performed based on the data from 14 studies with 3,656 patients to estimate the correlation between NLR and overall survival (OS) and progression-free survival (PFS) in NSCLC. Hazard ratio (HR) with 95% confidence interval (CI) were calculated to estimate the effect. We also conducted subgroup analysis and meta-regression analysis. The results demonstrated that elevated pretreatment NLR predicted poorer OS (HR: 1.70, 95% CI: 1.39–2.09) and PFS (HR: 1.63, 95% CI: 1.27–2.09) in patients with NSCLC. Subgroup analysis indicated that cut-off value of 5 showed consistently prognostic value. There was no significant heterogeneity or publication bias for OS and PFS for included studies. This meta-analysis revealed that elevated pretreatment NLR might be a predicative factor of poor prognosis for NSCLC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep12493

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 39

  1. Jemal, A. et al. Global Cancer Statistics. CA-Cancer J. Clin. 61, 69–90, 10.3322/caac.20107 (2011). · DOI · Paper page
  2. Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA-Cancer J. Clin. 62, 220–241, 10.3322/caac.21149 (2012). · DOI
  3. Paesmans, M. et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 13, 1221–1230 (1995). · DOI · Paper page
  4. Proctor, M. J. et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. British journal of cancer 103, 870–876, 10.1038/sj.bjc.6605855 (2010). · DOI
  5. Sieghart, W. et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology 57, 2224–2234, 10.1002/hep.26057 (2013). · DOI
  6. Gomez, D., Morris-Stiff, G., Toogood, G. J., Lodge, J. P. & Prasad, K. R. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 97, 513–518, 10.1002/jso.21001 (2008). · DOI
  7. McMillan, D. C. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer treatment reviews 39, 534–540, 10.1016/j.ctrv.2012.08.003 (2013). · DOI
  8. Sugiura, T., Uesaka, K., Kanemoto, H., Mizuno, T. & Okamura, Y. Elevated Preoperative Neutrophil-to-lymphocyte Ratio as a Predictor of Survival After Gastroenterostomy in Patients with Advanced Pancreatic Adenocarcinoma. Annals of surgical oncology 20, 4330–4337, 10.1245/s10434-013-3227-8 (2013). · DOI
  9. De Larco, J. E., Wuertz, B. R. & Furcht, L. T. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 4895–4900, 10.1158/1078-0432.ccr-03-0760 (2004). · DOI
  10. Kuang, D. M. et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. Journal of hepatology 54, 948–955, 10.1016/j.jhep.2010.08.041 (2011). · DOI
  11. Sun, Z. & Yang, P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. The Lancet. Oncology 5, 182–190, 10.1016/s1470-2045(04)01414-7 (2004). · DOI
  12. Horne, Z. D. et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. The Journal of surgical research 171, 1–5, 10.1016/j.jss.2011.03.068 (2011). · DOI
  13. Krenn-Pilko, S. et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. British journal of cancer 110, 2524–2530, 10.1038/bjc.2014.163 (2014). · DOI
  14. Stotz, M. et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. British journal of cancer 110, 435–440, 10.1038/bjc.2013.785 (2014). · DOI
  15. Limaye, A. R. et al. Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology 43, 757–764, 10.1111/hepr.12019 (2013). · DOI
  16. Hu, K., Lou, L., Ye, J. & Zhang, S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ open 5, e006404, 10.1136/bmjopen-2014-006404 (2015). · DOI
  17. Zhang, X., Zhang, W. & Feng, L. J. Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: a meta-analysis. PloS one 9, e111906, 10.1371/journal.pone.0111906 (2014). · DOI
  18. Unal, D., Eroglu, C., Kurtul, N., Oguz, A. & Tasdemir, A. Are Neutrophil/Lymphocyte and Platelet/Lymphocyte Rates in Patients with Non-Small Cell Lung Cancer Associated with Treatment Response and Prognosis? Asian Pac. J. Cancer Prev. 14, 5237–5242, 10.7314/apjcp.2013.14.9.5237 (2013). · DOI
  19. Yao, Y. W., Yuan, D. M., Liu, H. B., Gu, X. L. & Song, Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunology Immunotherapy 62, 471–479, 10.1007/s00262-012-1347-9 (2013). · DOI
  20. Cannon, N. A. et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors following stereotactic radiation therapy for early-stage non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10.1097/jto.0000000000000399 (2014). · DOI
  21. Kacan, T. et al. Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers? Asian Pac. J. Cancer Prev. 15, 2089–2094, 10.7314/apjcp.2014.15.5.2089 (2014). · DOI
  22. Pinato, D. J. et al. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. British journal of cancer, 10.1038/bjc.2014.145. (2014). · DOI
  23. Lee, Y. et al. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Journal of cancer research and clinical oncology 138, 2009–2016 (2012). · DOI
  24. Tomita, M., Shimizu, T., Ayabe, T., Yonei, A. & Onitsuka, T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer research 31, 2995–2998 (2011).
  25. Cedres, S. et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 14, 864–869, 10.1007/s12094-012-0872-5 (2012). · DOI
  26. Botta, C. et al. Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients. Cancer Biology and Therapy 14, 469–475 (2013). · DOI
  27. Forget, P. et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung and kidney cancer surgery. Annals of surgical oncology 20 Suppl 3, S650–660, 10.1245/s10434-013-3136-x (2013). · DOI
  28. Jafri, S. H., Shi, R. & Mills, G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): A retrospective review. BMC cancer 13, 10.1186/1471-2407-13-158. (2013). · DOI
  29. Lin, G. N. et al. Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. Asia Pac J Clin Oncol, 10.1111/ajco.12273 (2014). · DOI
  30. Choi, J. E. et al. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study. Cancer medicine, 10.1002/cam4.428 (2015). · DOI
  31. E, Y., He, N., Wang, Y. & Fan, H. Percutaneous transluminal angioplasty (PTA) alone versus PTA with balloon-expandable stent placement for short-segment femoropopliteal artery disease: a metaanalysis of randomized trials. Journal of vascular and interventional radiology : JVIR 19, 499–503, 10.1016/j.jvir.2007.12.446 (2008). · DOI
  32. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674, 10.1016/j.cell.2011.02.013 (2011). · DOI · Paper page
  33. Pillay, J. et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. Journal of Clinical Investigation 122, 327–336, 10.1172/jci57990 (2012). · DOI
  34. Motomura, T. et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. Journal of hepatology 58, 58–64, 10.1016/j.jhep.2012.08.017 (2013). · DOI
  35. Yang, X., Huang, Y., Feng, J. F. & Liu, J. S. Prognostic significance of neutrophil-to- lymphocyte ratio in esophageal cancer: a meta-analysis. OncoTargets and therapy 8, 789–794, 10.2147/ott.s77099 (2015). · DOI
  36. Yang, J. J. et al. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World journal of gastroenterology : WJG 21, 2807–2815, 10.3748/wjg.v21.i9.2807 (2015). · DOI
  37. Xiao, W.-K. et al. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. Bmc Cancer 14, 10.1186/1471-2407-14-117 (2014). · DOI
  38. Li, M.-X. et al. Prognostic role of neutrophil- to- lymphocyte ratio in colorectal cancer: A systematic review and meta- analysis. International Journal of Cancer 134, 2403–2413, 10.1002/ijc.28536 (2014). · DOI · Paper page
  39. Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16, 10.1186/1745-6215-8-16 (2007). · DOI · Paper page

Cited by

Metadata

Authors
Gu, X.-B., Tian, T., Tian, X.-J., & Zhang, X.-J.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2015-07-24
Volume
5
Issue
1
ISSN
2045-2322
DOI
10.1038/srep12493
Cited by
178
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.